

Caroline Kistorp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3841625/publications.pdf>

Version: 2024-02-01

81
papers

3,467
citations

257101

24
h-index

149479

56
g-index

81
all docs

81
docs citations

81
times ranked

5040
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure. <i>Circulation</i> , 2005, 112, 1756-1762.	1.6	554
2	N-Terminal Pro-Brain Natriuretic Peptide, C-Reactive Protein, and Urinary Albumin Levels as Predictors of Mortality and Cardiovascular Events in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1609.	3.8	463
3	Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) a multicentre, double-blind, randomised, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2017, 19, 69-77.	2.9	343
4	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 840-849.	5.5	159
5	Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study. <i>PLoS ONE</i> , 2016, 11, e0161208.	1.1	108
6	Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 215-218.	2.2	108
7	IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. <i>European Journal of Endocrinology</i> , 2009, 160, 25-31.	1.9	103
8	Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2182-2188.	1.8	98
9	Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 836.	3.0	95
10	Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status. <i>Endocrine</i> , 2013, 43, 626-634.	1.1	86
11	Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 106-116.	5.5	80
12	Low grade inflammation as measured by levels of YKL-40: Association with an increased overall and cardiovascular mortality rate in an elderly population. <i>International Journal of Cardiology</i> , 2010, 143, 35-42.	0.8	73
13	Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. <i>Reproductive BioMedicine Online</i> , 2017, 35, 121-127.	1.1	63
14	Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial. <i>American Heart Journal</i> , 2020, 228, 47-56.	1.2	61
15	Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2740-2751.	1.2	57
16	Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids. <i>Journal of Hypertension</i> , 2018, 36, 277-285.	0.3	49
17	Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?. <i>European Heart Journal</i> , 2020, 41, 1346-1353.	1.0	45
18	Cardiac systolic dysfunction in past illicit users of anabolic androgenic steroids. <i>American Heart Journal</i> , 2018, 203, 49-56.	1.2	40

#	ARTICLE	IF	CITATIONS
19	Long-term L-Triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised, double-blind, cross-over, placebo-controlled intervention study. <i>Clinical Endocrinology</i> , 2015, 83, 931-937.	1.2	38
20	Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). <i>Trials</i> , 2019, 20, 374.	0.7	35
21	Insulin sensitivity in relation to fat distribution and plasma adipocytokines among abusers of anabolic androgenic steroids. <i>Clinical Endocrinology</i> , 2017, 87, 249-256.	1.2	33
22	Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study. <i>BJU International</i> , 2019, 123, 602-611.	1.3	29
23	Prevalence and characteristics of diabetic patients in a chronic heart failure population. <i>International Journal of Cardiology</i> , 2005, 100, 281-287.	0.8	27
24	Biomarkers of endothelial dysfunction are elevated and related to prognosis in chronic heart failure patients with diabetes but not in those without diabetes. <i>European Journal of Heart Failure</i> , 2008, 10, 380-387.	2.9	26
25	Plasma YKL-40 levels are elevated in patients with chronic heart failure. <i>Scandinavian Cardiovascular Journal</i> , 2010, 44, 92-99.	0.4	24
26	Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: A prospective study. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 141-149.	1.5	24
27	Cardiomyocyte Expression and Cell-specific Processing of Procholecystokinin. <i>Journal of Biological Chemistry</i> , 2015, 290, 6837-6843.	1.6	24
28	Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial. <i>Journal of Urology</i> , 2017, 197, 1441-1447.	0.2	24
29	Defensins and outcome in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 387-394.	2.9	22
30	Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 80.	0.7	22
31	A protocol for a randomised, double-blind, placebo-controlled study of the effect of Liraglutide on left Ventricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>	0.7	21
32	Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity. <i>BMC Obesity</i> , 2014, 1, 24.	3.1	21
33	Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 117.	0.7	21
34	Hyperprolactinemia and the Association with All-Cause Mortality and Cardiovascular Mortality. <i>Hormone and Metabolic Research</i> , 2017, 49, 411-417.	0.7	21
35	Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. <i>Endocrine Connections</i> , 2018, 7, 115-123.	0.8	21
36	Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation. <i>ESC Heart Failure</i> , 2019, 6, 983-991.	1.4	21

#	ARTICLE	IF	CITATIONS
37	Iron deficiency: Prevalence and relation to cardiovascular biomarkers in heart failure outpatients. <i>International Journal of Cardiology</i> , 2015, 195, 143-148.	0.8	20
38	Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study. <i>European Journal of Endocrinology</i> , 2018, 178, 65-74.	1.9	18
39	Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 585-597.	1.4	18
40	Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	17
41	N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. <i>Clinical Endocrinology</i> , 2007, 66, 619-625.	1.2	16
42	Prevalence of heart failure and the diagnostic value of MRâ€proANP in outpatients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 736-740.	2.2	16
43	The impact of the glucagonâ€like peptideâ€1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2141-2150.	2.2	16
44	Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial. <i>Diabetes and Metabolism</i> , 2020, 47, 101190.	1.4	15
45	Complement activation, endothelial dysfunction, insulin resistance and chronic heart failure. <i>Scandinavian Cardiovascular Journal</i> , 2010, 44, 260-266.	0.4	14
46	Quantification of visceral adipose tissue in polycystic ovary syndrome: dual-energy X-ray absorptiometry versus magnetic resonance imaging. <i>Acta Radiologica</i> , 2018, 59, 13-17.	0.5	14
47	Mineralocorticoid Receptor Antagonist Improves Cardiac Structure inâ€Type 2â€Diabetes. <i>JACC: Heart Failure</i> , 2021, 9, 550-558.	1.9	14
48	Risk Stratification in Secondary Prevention. <i>Circulation</i> , 2006, 114, 184-186.	1.6	13
49	Plasma von Willebrand factor and soluble E-selectin levels in stable outpatients with systolic heart failure: The Frederiksberg heart failure study. <i>International Journal of Cardiology</i> , 2007, 119, 80-82.	0.8	13
50	Plasma calprotectin levels reflect disease severity in patients with chronic heart failure. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 999-1004.	0.8	13
51	Procoagulant State in Current and Former Anabolic Androgenic Steroid Abusers. <i>Thrombosis and Haemostasis</i> , 2018, 47, 647-653.	1.8	13
52	Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, doubleâ€blind, placeboâ€controlled trial (MIRAD trial). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2305-2314.	2.2	13
53	Serum Insulin-like Factor 3 Levels Are Reduced in Former Androgen Users, Suggesting Impaired Leydig Cell Capacity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2664-e2672.	1.8	13
54	Endogenous Testosterone Levels Are Associated with Risk of Type 2 Diabetes in Women without Established Comorbidity. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa050.	0.1	12

#	ARTICLE	IF	CITATIONS
55	Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020418.	1.6	12
56	Associations between plasma insulin-like growth factor-I and the markers of inflammation interleukin 6, C-reactive protein and YKL-40 in an elderly background population. <i>Inflammation Research</i> , 2010, 59, 503-510.	1.6	11
57	Prevalence of early stages of heart failure in an elderly risk population: the Copenhagen Heart Failure Risk Study. <i>Open Heart</i> , 2019, 6, e000840.	0.9	11
58	Association Between 3-Iodothyronamine (T1) Concentrations and Left Ventricular Function in Chronic Heart Failure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1232-1238.	1.8	10
59	Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events. <i>Scandinavian Cardiovascular Journal</i> , 2020, 54, 294-299.	0.4	10
60	The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker). <i>Cardiovascular Diabetology</i> , 2022, 21, 34.	2.7	10
61	Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 22.	0.7	9
62	Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low-Risk Population With Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2021, 10, e020395.	1.6	9
63	N-Terminal-Pro-B-type Natriuretic Peptide in Acute Hyperthyroidism. <i>Thyroid</i> , 2007, 17, 237-241.	2.4	8
64	Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). <i>Circulation</i> , 2021, 143, 2208-2210.	1.6	8
65	MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction. <i>Cardiovascular Diabetology</i> , 2020, 19, 180.	2.7	7
66	Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease. <i>European Journal of Heart Failure</i> , 2020, 22, 813-820.	2.9	6
67	The Mineralocorticoid Receptor Antagonist Eplerenone Suppresses Interstitial Fibrosis in Subcutaneous Adipose Tissue in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2021, 70, 196-203.	0.3	6
68	Anabolic Androgenic Steroid Abuse Impairs Fibrin Clot Lysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 011-017.	1.5	6
69	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. <i>International Journal of Cardiovascular Imaging</i> , 2021, , 1.	0.7	6
70	Biochemical Cardiac Risk Markers in the General Population, Hypertension and Coronary Artery Disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2005, 65, 138-142.	0.6	5
71	The Influence of Diabetes Mellitus on Midregional Proadrenomedullin Concentrations and Prognostic Value in Heart Failure Outpatients. <i>Journal of Cardiac Failure</i> , 2015, 21, 250-257.	0.7	5
72	Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 948-961.	2.0	5

#	ARTICLE	IF	CITATIONS
73	Effect of Anabolicâ€“Androgenic Steroid Abuse on the Contact Activation System. Thrombosis and Haemostasis, 2021, 121, 1268-1273.	1.8	4
74	Early Stages of Obesity-related Heart Failure Are Associated with Natriuretic Peptide Deficiency and an Overall Lack of Neurohormonal Activation: The Copenhagen Heart Failure Risk Study. Global Heart, 2020, 15, 25.	0.9	3
75	Evaluation of ICD-10 algorithms to identify hypopituitary patients in the Danish National Patient Registry. Clinical Epidemiology, 2017, Volume 9, 75-82.	1.5	2
76	Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study. Biomarkers, 2020, 25, 248-259.	0.9	2
77	Letter to the Editor: â€œRate and Extent of Recovery from Reproductive and Cardiac Dysfunction Due to Androgen Abuse in Menâ€œ. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3028-e3029.	1.8	1
78	Association between early detected heart failure stages and future cardiovascular and non-cardiovascular events in the elderly (Copenhagen Heart Failure Risk Study). BMC Geriatrics, 2022, 22, 230.	1.1	1
79	Sodiumâ€“Glucose Cotransporterâ€“2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives. Basic and Clinical Pharmacology and Toxicology, 2022, , .	1.2	1
80	The Effect of Empagliflozin on Contractile Reserve in Heart Failure: Prespecified Sub-Study of a Randomized, Double-Blind, and Placebo-Controlled Trial. American Heart Journal, 2022, 250, 57-57.	1.2	1
81	MON-114 Effect of Selective Mineralocorticoid Receptor Antagonist on liver Fat and Metabolism in Patients with Type 2 Diabetes: A Randomized Controlled Trail. Journal of the Endocrine Society, 2019, 3, .	0.1	0